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Background
HIV-1 infected patients on HAART were treated with
mRNA electroporated autologous dendritic cells (DC) in
a phase I/II clinical trial and the effect of active immune
therapy on immune responses and viral sequence evolu-
tion was evaluated.
Methods
HIV patients (n = 17) were vaccinated with DC expressing
Tat, Rev and Nef. After four vaccinations HAART treat-
ment was interrupted. PBMC taken during and after vacci-
nation were screened with Elispot, using either peptides or
electroporated DC for restimulation.
For sequence analysis, HIV RNA was amplified by RT-
PCR; sequence variation in vaccine and control genes was
analyzed pre- and post-vaccination.
Results
In 12 out of 16 patients screened with both peptide and
DC Elispot, increased post-vaccination responses to vac-
cine-antigens were found. In 12/17 patients a complete
set of both pre-HAART and post-vaccination sequences
was obtained. With one exception, variation in pre-
HAART and post vaccination HIV sequences was limited.
Viral sequences spanning specific HLA restricted epitopes
showed evidence of viral evolution, but this was not a
common phenomenon.
Conclusion
The immune therapy was well-tolerated and did not have
adverse effects. Increased cellular immunity against the
antigens could be demonstrated. The enhanced immunity
resulted in higher sequence variability in vaccine genes
than control genes, although the effects were limited.
There was no significant correlation between the breadth
and/or extent of the immune response and the rate of
virus evolution.
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